Q&A with Prothena’s Ansgar Conrad answers questions about the company’s partnership with ASPIRE
Q: What is ASPIRE?
A: The Amyloidosis Stakeholder Partnerships for Impact Reach and Equity (ASPIRE) is a collaborative of biotech and pharmaceutical companies committed to improving diagnosis, systems of care, and health equity for patients suffering from amyloidosis, a rare disease caused by protein build-up.
Q: What is ASPIRE’s goal?
A: ASPIRE aims to accelerate through collaborative project design and shared resources, arriving at solutions that address common challenges and unmet need. The collaborating companies are leading companies in pre-competitive phases working together to address some of the most urgent issues faced by the amyloidosis community. Ultimately, through this partnership, ASPIRE aims to shift the discourse and demonstrate what can be done when leaders work together on behalf of rare disease patients.
Q: What does the partnership mean to Prothena?
A: Amyloidosis can affect the heart, kidneys, liver, nervous system, and digestive tract. Although it is a rare disease, the range of organs that can be affected poses a broad challenge for the biotech industry. This is a cruel disease that deserves the industry’s focused attention, and we at Prothena are pleased to play a role in this effort.
Q: Tell us more about why partnerships like ASPIRE are important to the industry.
A: We welcome the opportunity to work alongside other biopharma companies. There’s no question that the collaboration of the scientific community is imperative to expediate solutions for patients and their families, with the ultimate goal of reducing the societal toll these diseases will inevitably take.
Learn more about Prothena’s hand in ASPIRE here.